← Eichor
Condition: Intermediate Risk Acute Myeloid Leukemia Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Intermediate Risk Acute Myeloid Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens
Phase 2/Phase 3 · 56 location(s) · University Hospital, Angers · NCT02416388Intermediate-dose HAD Regimen for CEBPA Double-mutated AML
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06529250Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Inte
Phase 3 · 1 location(s) · Yehui Tan · NCT06990321Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
Phase 3 · 48 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT04168502Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Phase 1 · 2 location(s) · OHSU Knight Cancer Institute · NCT04659616VA Consolidation in Intermediate-Risk AML
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07672262Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.
Phase 2 · 1 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT06483906Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1
Phase 3 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06744504A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT06928376Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06394011CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
Phase 2 · 35 location(s) · Centre Hospitalier Universitaire de Nice · NCT05260528Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
Phase 1/Phase 2 · 2 location(s) · Ohio State University Comprehensive Cancer Center · NCT04049539Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT07259707Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidin
Phase 2 · 178 location(s) · National Cancer Institute (NCI) · NCT05554393Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML
Phase 2 · 5 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07304232
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.